Opicapone

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Opicapone
   1. Pharmacist Assessment Report
   2. Opicapone: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Opicapone: Known uses and market status in Australia

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Opicapone, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The known use listed below is supported by a licence in another country.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
juvenile onset Parkinson disease 19A	licence in another country (approved indication: parkinson disease)

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
13206C	Ongentys	Capsule 50 mg	Valid

Safety Considerations

Drug Interactions: The interaction screen identified 53 potential interactions. The main ones from the listed entries are below.

• Major: methylene blue.
• Moderate (examples):
  • Sympathomimetics: epinephrine (systemic, ophthalmic and topical forms) and sibutramine.
  • Opioids and related drugs: morphine (including liposomal), codeine, opium, diphenoxylate and difenoxin.
  • Cannabinoids: dronabinol and nabilone.
  • Sedating antihistamines: promethazine, chlorpheniramine, cetirizine and nasal azelastine.
  • Others: metoclopramide, dextromethorphan and ethanol.

For warnings and contraindications, please refer to the TGA-approved Product Information (PI) for safety information.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---